Verana Health®

DATASHEET
Prostate Cancer

Qdata® Prostate Cancer is a real-world dataset on more than 468,000 patients with exclusive access to key variables including PSA level, Gleason score, TNM staging, castration resistance and treatment patterns to better understand the patient journey.

Verana Health® powers urologic research using exclusive real-world data from the American Urological Association (AUA) Quality Registry (AQUA) and other sources, such as medical and pharmacy claims.

- **Exclusive Insights into the Prostate Cancer Population**
  Only found here
- **Unique Understanding of Prostate Cancer Disease Progression**
  View prostate cancer biomarkers such as PSA level or Gleason score
- **Earlier View into the Prostate Cancer Patient Journey**
  View into treatment path choices from urologist electronic health records (EHRs)

In Qdata Prostate Cancer:

468K+	2.9yrs	464K+
De-identified patients with Prostate Cancer*	Follow up data w/linked claims	De-identified patients linked w/ claims data**

*Defined as patients in AQUA who have ICD-9-CM 185 or ICD-10-CM C61 AND a Gleason score of 6 or above
** Defined as patients in AQUA who were diagnosed >= 2015 and ICD-9-CM 185 or ICD-10-CM C61 AND a Gleason score of 6 or above and link with at least one open or closed Komodo Health medical/pharmacy claims data. Data current to January 2025.

Key Variables

TNM Stage	TNM Stage (Clinical or Pathological)*	Unique Patients in Qdata Prostate Cancer
TNM stages are extracted from unstructured clinical notes at an encounter level and can be used to inform risk stratification. TNM staging is frequently not supplied by the urologist.	T-stage	173,000
	N-stage	96,000
	M-stage	63,000

*These categories are not mutually exclusive

Verana Health®

DATASHEET
Prostate Cancer

Demographics

Patient Age



Patient Race



Metastatic Progression

Metastatic progression refers to the spread of cancer from its original site to other parts of the body. We define a patient as metastatic from NLP approaches on unstructured clinician notes.

Metastasis (at Any Point in Time)	
Metastasis Stage	**Estimated Unique Patients in Qdata Prostate Cancer**
M0*	75,000
Metastatic (from TNM staging, M1)*	9,200
Metastatic (from clinical documentation)*	40,800
Metastatic Total	42,700

*Patients are not mutually exclusive

We capture approximately **5x more instances** of metastasis when expanding from the explicit documentation of the TNM staging system to including more implicit types of evidence.

Gleason Score

Gleason score is curated from clinical notes based on biopsy samples and describes how aggressive the cancer cells are. 100% of patients in Qdata Prostate Cancer have at least one Gleason score captured.

Distinct Patient Count By Highest Gleason Score



Qdata. Prostate Cancer

Potential Applications:

- Clinical Development
- HEOR & Medical Affairs
- Commercialization

Ways to Engage Us

- Intuitive Dashboards
- Custom Insights via Services
- Direct Data Access

*** Data current to June 2026. Data counts represented are subject to change.**
Data counts for research purposes are dependent on project scope and feasibility.

Want to learn more?

Talk to a team member today
team@veranahealth.com

veranahealth.com/uro-request

About Verana Health

Verana Health, Inc.® is a digital health company revolutionizing patient care and clinical research by utilizing physician expertise and artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world's largest patient data sources in oncology, ophthalmology, neurology, and urology. Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care and quality of life for patients, and life sciences companies rely on the insights to accelerate the development of new therapies.

For more information, visit www.veranahealth.com

© 2026 Verana Health | Datasheet | Prostate Cancer